Investigating the safety and efficacy of hematopoietic and mesenchymal stem cell transplantation for treatment of T1DM: a systematic review and meta-analysis

[1] Nordwall M(2004)Declining incidence of severe retinopathy and persisting decrease of nephropathy in an unselected population of type 1 diabetes—the Linköping Diabetes Complications Study Diabetologia 47 1266-1272

[2] Skrivarhaug T(2006)Low risk of overt nephropathy after 24 yr of childhood-onset type 1 diabetes mellitus (T1DM) in Norway Pediatr Diabetes 7 239-246

[3] Kreisel W(2003)Complete remission of Crohn’s disease after high-dose cyclophosphamide and autologous stem cell transplantation Bone Marrow Transplant 32 337-1256

[4] Mannon PJ(2011)Remestemcel-L: human mesenchymal stem cells as an emerging therapy for Crohn’s disease Expert Opin Biol Ther 11 1249-S170

[5] Martin P(2010)Prochymal improves response rates in patients with steroid-refractory acute graft versus host disease (SR-GVHD) involving the liver and gut: results of a randomized, placebo-controlled, multicenter phase III trial in GVHD Biol Blood Marrow Transplant 16 S169-1412

[6] Matar AA(2014)Stem cell therapy for cardiac dysfunction Springerplus 3 440-3046

[7] Chong JJ(2007)Stem/progenitor cell sources of insulin-producing cells for the treatment of diabetes Tissue Eng 13 1399-190

[8] Lock LT(2014)Mesenchymal stem cell-based treatment for microvascular and secondary complications of diabetes mellitus Front Endocrinol 5 86-1085

[9] Tzanakakis ES(2014)Autologous nonmyeloablative hematopoietic stem cell transplantation in new-onset type 1 diabetes: a multicenter analysis Diabetes 63 3041-9282

[10] Davey GC(2012)Mesenchymal stem cell-based therapy for the treatment of type 1 diabetes mellitus Curr Stem Cell Res Ther 7 179-4492

[1] Nordwall M(2004)Declining incidence of severe retinopathy and persisting decrease of nephropathy in an unselected population of type 1 diabetes—the Linköping Diabetes Complications Study Diabetologia 47 1266-1272

[2] Skrivarhaug T(2006)Low risk of overt nephropathy after 24 yr of childhood-onset type 1 diabetes mellitus (T1DM) in Norway Pediatr Diabetes 7 239-246

[3] Kreisel W(2003)Complete remission of Crohn’s disease after high-dose cyclophosphamide and autologous stem cell transplantation Bone Marrow Transplant 32 337-1256

[4] Mannon PJ(2011)Remestemcel-L: human mesenchymal stem cells as an emerging therapy for Crohn’s disease Expert Opin Biol Ther 11 1249-S170

[5] Martin P(2010)Prochymal improves response rates in patients with steroid-refractory acute graft versus host disease (SR-GVHD) involving the liver and gut: results of a randomized, placebo-controlled, multicenter phase III trial in GVHD Biol Blood Marrow Transplant 16 S169-1412

[6] Matar AA(2014)Stem cell therapy for cardiac dysfunction Springerplus 3 440-3046

[7] Chong JJ(2007)Stem/progenitor cell sources of insulin-producing cells for the treatment of diabetes Tissue Eng 13 1399-190

[8] Lock LT(2014)Mesenchymal stem cell-based treatment for microvascular and secondary complications of diabetes mellitus Front Endocrinol 5 86-1085

[9] Tzanakakis ES(2014)Autologous nonmyeloablative hematopoietic stem cell transplantation in new-onset type 1 diabetes: a multicenter analysis Diabetes 63 3041-9282

[10] Davey GC(2012)Mesenchymal stem cell-based therapy for the treatment of type 1 diabetes mellitus Curr Stem Cell Res Ther 7 179-4492